Vertex, in a partnership with CRISPR Therapeutics (NASDAQ:CRSP), recently announced encouraging phase 1/2 trial results from a gene-editing therapy in two genetic blood disorders.While other companies lowered annual guidance due to the coronavirus crisis, Vertex increased its outlook for product sales.